Hereditary Angioedema Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | KalVista Pharma, Intellia Therapeutics, BioMarin Pharma, CSL Behring, Ionis Pharma

DelveInsight's "Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Hereditary Angioedema market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hereditary Angioedema Market Forecast
https://www.delveinsight.com/sample-request/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Hereditary Angioedema Market Report:
The Hereditary Angioedema market size was valued approximately USD 2,300 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In 2023, the United States held the largest market size for HAE, reaching approximately USD 2,000 million, and this market is projected to grow during the forecast period.
Currently, three categories of medications are utilized for the long-term prevention of type 1 and type 2 Hereditary Angioedema (HAE): C1-inhibitors (C1-INHs), 17 alpha-alkylated androgens, and antifibrinolytics.
In 2023, France recorded the largest market size among the EU4 and the UK, approximately USD 100 million.
In June 2024, KalVista has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for sebetralstat, an innovative investigational oral plasma kallikrein inhibitor designed to treat HAE attacks in adults and pediatric patients aged 12 and older.
In August 2024, Astria Therapeutics has chosen Ypsomed as its partner for the development of an autoinjector for STAR-0215.
In May 2024, Ionis Pharmaceuticals reported encouraging findings from the Phase III OASIS-HAE and OASISplus trials of donidalorsen for hereditary angioedema (HAE). The studies demonstrated substantial and sustained decreases in monthly HAE attack rates, with over 90% improvement observed after one year of treatment, regardless of whether the drug was administered monthly or bi-monthly. The results are set to be presented at the 2024 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress in Valencia and will be published in The New England Journal of Medicine.
In 2023, approximately 7,000 diagnosed cases of hereditary angioedema (HAE) were reported in the United States.
Type I Hereditary Angioedema (HAE) accounted for the largest share of diagnosed patients in the US, with approximately 5,500 cases reported in 2023.
DelveInsight's analysts estimated that there were around 1,000 diagnosed cases in the age group of 17 to under 65 years in 2023.
Key Hereditary Angioedema Companies: Shire, Ionis Pharmaceuticals, Astria Therapeutics, Intellia Therapeutics, BioMarin Pharmaceutical, CSL Behring, Ionis Pharmaceuticals, Astria Therapeutics, Pharvaris Netherlands B.V, Takeda, KalVista Pharmaceuticals, CSL Behring, and others
Key Hereditary Angioedema Therapies: Firazyr, Donidalorsen (IONIS-PKK-LRx), Navenibart (STAR-0215), NTLA-2002, KVD900, NTLA-2002, BMN 331, Garadacimab, Donidalorse, STAR-0215, PHA121, NTLA-2002, TAK-743, KVD900, CSL312, Lanadelumab, and others
The Hereditary Angioedema epidemiology based on gender analyzed that the diagnosed prevalent cases of Hereditary Angioedema in the 7MM varied according to gender, with prevalent cases higher in females than males
The Hereditary Angioedema market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hereditary Angioedema pipeline products will significantly revolutionize the Hereditary Angioedema market dynamics.

Hereditary Angioedema Overview
Rarely occurring hereditary angioedema (HAE) is characterized by recurrent episodes of localized subcutaneous (SC) or mucosal edema, most commonly affecting the oropharynx, upper respiratory tract, skin, and intestines.

Get a Free sample for the Hereditary Angioedema Market Report:
https://www.delveinsight.com/report-store/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hereditary Angioedema Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hereditary Angioedema Epidemiology Segmentation:
The Hereditary Angioedema market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
Total Prevalence of Hereditary Angioedema
Prevalent Cases of Hereditary Angioedema by severity
Gender-specific Prevalence of Hereditary Angioedema
Diagnosed Cases of Episodic and Chronic Hereditary Angioedema

Download the report to understand which factors are driving Hereditary Angioedema epidemiology trends @ Hereditary Angioedema Epidemiology Forecast
https://www.delveinsight.com/sample-request/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hereditary Angioedema Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hereditary Angioedema market or expected to get launched during the study period. The analysis covers Hereditary Angioedema market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hereditary Angioedema Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hereditary Angioedema Therapies and Key Companies
Firazyr: Shire/Takeda
Donidalorsen (IONIS-PKK-LRx): Ionis Pharmaceuticals
Navenibart (STAR-0215): Astria Therapeutics
NTLA-2002: Intellia Therapeutics
KVD900: KalVista Pharmaceuticals
NTLA-2002: Intellia Therapeutics
BMN 331: BioMarin Pharmaceutical
Garadacimab: CSL Behring
Donidalorse: Ionis Pharmaceuticals
STAR-0215: Astria Therapeutics
PHA121: Pharvaris Netherlands B.V
NTLA-2002: Intellia Therapeutics
TAK-743: Takeda
KVD900: KalVista Pharmaceuticals
CSL312: CSL Behring
Lanadelumab: Shire

Discover more about therapies set to grab major Hereditary Angioedema market share @ Hereditary Angioedema Treatment Market
https://www.delveinsight.com/sample-request/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hereditary Angioedema Market Strengths
Increasing identification of a novel genetic mutation in various regions warranting further focus on the types and associated pathophysiology, including recognition of hormonal changes

Hereditary Angioedema Market Opportunities
Proliferating demand for therapies with improved patient compliance, fewer side effects, improved resistance profile, and long-acting therapies

Scope of the Hereditary Angioedema Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Hereditary Angioedema Companies: Shire, Ionis Pharmaceuticals, Astria Therapeutics, Intellia Therapeutics, BioMarin Pharmaceutical, CSL Behring, Ionis Pharmaceuticals, Astria Therapeutics, Pharvaris Netherlands B.V, Takeda, KalVista Pharmaceuticals, CSL Behring, and others
Key Hereditary Angioedema Therapies: Firazyr, Donidalorsen (IONIS-PKK-LRx), Navenibart (STAR-0215), NTLA-2002, KVD900, NTLA-2002, BMN 331, Garadacimab, Donidalorse, STAR-0215, PHA121, NTLA-2002, TAK-743, KVD900, CSL312, Lanadelumab, and others
Hereditary Angioedema Therapeutic Assessment: Hereditary Angioedema current marketed and Hereditary Angioedema emerging therapies
Hereditary Angioedema Market Dynamics: Hereditary Angioedema market drivers and Hereditary Angioedema market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Hereditary Angioedema Unmet Needs, KOL's views, Analyst's views, Hereditary Angioedema Market Access and Reimbursement

To know more about Hereditary Angioedema companies working in the treatment market, visit @ Hereditary Angioedema Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Hereditary Angioedema Market Report Introduction
2. Executive Summary for Hereditary Angioedema
3. SWOT analysis of Hereditary Angioedema
4. Hereditary Angioedema Patient Share (%) Overview at a Glance
5. Hereditary Angioedema Market Overview at a Glance
6. Hereditary Angioedema Disease Background and Overview
7. Hereditary Angioedema Epidemiology and Patient Population
8. Country-Specific Patient Population of Hereditary Angioedema
9. Hereditary Angioedema Current Treatment and Medical Practices
10. Hereditary Angioedema Unmet Needs
11. Hereditary Angioedema Emerging Therapies
12. Hereditary Angioedema Market Outlook
13. Country-Wise Hereditary Angioedema Market Analysis (2020-2034)
14. Hereditary Angioedema Market Access and Reimbursement of Therapies
15. Hereditary Angioedema Market Drivers
16. Hereditary Angioedema Market Barriers
17. Hereditary Angioedema Appendix
18. Hereditary Angioedema Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Hereditary Angioedema Pipeline https://www.delveinsight.com/report-store/hereditary-angioedema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Hereditary Angioedema Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Hereditary Angioedema market. A detailed picture of the Hereditary Angioedema pipeline landscape is provided, which includes the disease overview and Hereditary Angioedema treatment guidelines.

Hereditary Angioedema Epidemiology https://www.delveinsight.com/report-store/hereditary-angioedema-hae-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Hereditary Angioedema Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Hereditary Angioedema epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports Offered By DelveInsight:

Nasolabial Fold Market: https://www.delveinsight.com/report-store/nasolabial-fold-market
Ventricular Fibrillation Market: https://www.delveinsight.com/report-store/ventricular-fibrillation-market
Facial Lines Market: https://www.delveinsight.com/report-store/facial-lines-market
Germ Cell Tumor Market: https://www.delveinsight.com/report-store/germ-cell-tumor-market
Hyperglycemia Market: https://www.delveinsight.com/report-store/hyperglycemia-market
Valley Fever Market: https://www.delveinsight.com/report-store/valley-fever-market
Hemostasis Market: https://www.delveinsight.com/report-store/hemostasis-market
Pharmaceutical Consulting Companies: https://www.delveinsight.com/consulting
Car T Cell Therapy Market: https://www.delveinsight.com/report-store/chimeric-antigen-receptor-car-t-cell-therapy-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.